(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 November 2003 (27.11.2003)

PCT

(10) International Publication Number
WO 03/097099 A1

(51) International Patent Classification[7]: A61K 45/06, 31/41, 31/135 // (A61K 31/41, 31:135)

(21) International Application Number: PCT/EP03/05198

(22) International Filing Date: 16 May 2003 (16.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/381,548 17 May 2002 (17.05.2002) US

(71) Applicant *(for all designated States except AT, US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(71) Applicant *(for AT only)*: **NOVARTIS PHARMA GMBH** [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **CALIFF, Robert, M.** [US/US]; 3917 ColoradO Street, Durham, NC 22707 (US). **MACNAB, Malcolm** [US/US]; 50 Liberty Corner Road, Far Hills, NJ 07931 (US). **McMURRAY, John, J., V.** [IE/GB]; 5 Thorn Drive, Bearsden, Glasgow, Scotland (GB). **PFEFFER, Marc, A.** [US/US]; 1110 West Roxbury Parkway, Chestnut Hill, MA 02467 (US).

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (NE).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/097099 A1

(54) Title: COMBINATION OF ANGIOTENSIN II RECEPTOR BLOCKER AND BETA-BLOCKER FOR SECONDARY PREVENTION OF MYOCARDIAL INFARCTION

(57) Abstract: The invention relates to a method of treating cardiovascular disease in patients following myocardial infarction comprising administering an effective amount of an ARB, especially valsartan, in combination within an effective amount of a beta-blocker to such patients.